Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05161598
Expanded Access Status : No longer available
First Posted : December 17, 2021
Last Update Posted : June 27, 2022
Sponsor:
Information provided by (Responsible Party):
Janssen Research & Development, LLC

Brief Summary:
Teclistamab pre-approval access in relapsed or refractory multiple myeloma.

Condition or disease Intervention/treatment
Multiple Myeloma Drug: Teclistamab

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Individual Patients
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: PRE-APPROVAL ACCESS (PAA) Single Patient Request (SPR) TREATMENT GUIDELINES for Teclistamab (JNJ-64007957) for Treating Physician Use



Intervention Details:
  • Drug: Teclistamab
    Teclistamab will be administered subcutaneously (SC).
    Other Name: JNJ-64007957

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Criteria
Must have relapsed/refractory multiple myeloma (RRMM) and have evidence of disease progression after last therapy. Must have exhausted all available treatment options accessible as local standard of care (example. proteasome inhibitors [PIs], immunomodulatory imide drugs [IMIDs], anti CD38 monoclonal antibodies [mAbs] and therapies targeting Exportin 1 [XPO1] and B cell maturation antigen [BCMA]). Must not be eligible for a clinical trial with teclistamab or other medicines in this setting

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05161598


Locations
Layout table for location information
Denmark
DUMMY
Dummy, Denmark, 99999
Estonia
DUMMY
Dummy, Estonia, 99999
Iceland
DUMMY
Dummy, Iceland, 99999
Ireland
DUMMY
Dummy, Ireland, 99999
Israel
DUMMY
Dummy, Israel, 99999
Italy
DUMMY
Dummy, Italy, 99999
Lithuania
DUMMY
Dummy, Lithuania, 99999
Portugal
DUMMY
Dummy, Portugal, 99999
Romania
DUMMY
Dummy, Romania, 99999
Switzerland
DUMMY
Dummy, Switzerland, 99999
Sponsors and Collaborators
Janssen Research & Development, LLC
Investigators
Layout table for investigator information
Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC
Layout table for additonal information
Responsible Party: Janssen Research & Development, LLC
ClinicalTrials.gov Identifier: NCT05161598    
Other Study ID Numbers: CR108846
64007957PTL4001 ( Other Identifier: Janssen Research & Development, LLC )
First Posted: December 17, 2021    Key Record Dates
Last Update Posted: June 27, 2022
Last Verified: June 2022
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases